InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,100.00
(
2.07%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.54
(
-0.03%
)
Bitcoin
66,592.84
(
0.27%
)
Post# of 4423
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

BooDog

Send PM Follow Ignore
Followers 229
Posts 21457
Boards Moderated 2
Alias Born 08/03/2006

BooDog

Re: None

Thursday, 03/16/2017 8:19:21 AM

Thursday, March 16, 2017 8:19:21 AM

Post# of 4423
$CTIX Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease



Brilacidin






Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease

March 16, 2017

http://www.cellceutix.com/press-release/2017/3/15/cellceutixs-phase-2-drug-candidate-brilacidin-emerging-as-a-potential-novel-non-biologic-therapy-in-treating-inflammatory-bowel-disease

Expecting Prurisol P2b interim data in April though they may squeeze it out end of March. Halfway point just passed depending on how many patients they had from the get go.

Kevetrin moving forward as well.

http://www.cellceutix.com/press-release/

"Perfection is not attainable, but if we chase perfection we can catch
excellence." Vince Lombardi
Do your research! Play the TA. All posts are my opinion.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up